Full-Time

Accounting Manager

Posted on 9/4/2026

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

Compensation Overview

$125k - $145k/yr

+ Company equity + Bonus participation

San Diego, CA, USA

In Person

Bachelor's

Category
Accounting (1)
Required Skills
NetSuite
SAP Products
Oracle
Excel/Numbers/Sheets

Get referred to Maravai LifeSciences

See people who can refer or advise you

Requirements
  • A bachelor's degree in Accounting, Finance, or a related field and at least 5–7 years of progressive accounting experience, including at least 2 years in a management or supervisory role.
  • An active Certified Public Accountant credential or progress toward it is required.
  • Strong working knowledge of United States Generally Accepted Accounting Principles, including equity accounting under ASC 718.
  • Demonstrated experience in a public company environment, including Sarbanes-Oxley compliance and internal controls over financial reporting.
  • Proficiency in enterprise resource planning systems such as NetSuite, SAP, Oracle, or comparable systems, with advanced Microsoft Excel skills.
  • Exceptional attention to detail, analytical rigor, and organizational skills, with the ability to manage multiple priorities and deadlines in a fast-paced environment.
  • Strong interpersonal and communication skills with the ability to partner effectively across functions and levels, including senior leadership.
  • A high degree of integrity and sound judgment, with the ability to handle sensitive financial data with discretion and professionalism.
Responsibilities
  • Lead and manage the monthly and quarterly close process, ensuring timely and accurate completion of all general ledger activities.
  • Own and review journal entries across key areas including accruals and prepaids.
  • Oversee cash accounting, bank reconciliations, and intercompany accounting, including elimination entries and intercompany settlement.
  • Review and approve balance sheet account reconciliations, ensuring completeness, accuracy, and timely resolution of reconciling items.
  • Maintain and enforce the close calendar, coordinating with cross-functional stakeholders to meet reporting deadlines.
  • Partner with Financial Planning and Analysis to support variance analysis and provide commentary on significant general ledger fluctuations.
  • Prepare and review financial statement disclosures and support the preparation of internal financial reporting packages.
  • Support Securities and Exchange Commission reporting, including Forms 10-Q and 10-K, preparation or review of earnings-per-share calculations, footnotes, and supporting schedules.
  • Ensure compliance with United States Generally Accepted Accounting Principles, including review and application of relevant accounting standards to transactions and estimates.
  • Maintain and strengthen Sarbanes-Oxley-compliant internal controls over financial reporting, including documentation and testing support.
  • Coordinate with external auditors for quarterly reviews and annual audits, including timely preparation of prepared-by-client schedules and audit support packages.
  • Own equity plan administration, including oversight of the external Certified Equity Professional, administration of restricted stock unit and stock option plans, grant processing, vesting, exercises, and employee stock purchase plan transactions.
  • Review journal entries, reconciliations, and financial statement disclosures related to equity compensation.
  • Manage and approve payroll-related equity and stock transactions, including tax updates and reconciliations.
  • Maintain equity system data integrity in Fidelity.
  • Serve as the primary liaison with the transfer agent and brokerage partner to ensure accuracy of share issuances, plan reserves, and reporting.
  • Manage, coach, and develop accounting staff, fostering a high-performance team culture focused on accuracy, accountability, and growth.
  • Identify and implement process improvements to enhance accuracy, efficiency, and compliance.
  • Support special projects, system implementations, and ad hoc financial analyses.
  • Perform other functions and duties as required.
Desired Qualifications
  • Experience with automation or close management tools.
  • Experience with equity administration platforms such as Certent/Equity Edge, Fidelity, or comparable platforms.
  • Experience supporting Securities and Exchange Commission reporting, including Forms 10-Q and 10-K, and partnering with external auditors.

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Get referred to Maravai LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $51.4 million, with TriLink up 11.5% and Cygnus growing.
  • Management raised 2026 adjusted EBITDA guidance to $33 million-$35 million on August 6.
  • Base TriLink revenue grew 13.4% in first-half 2026, excluding COVID CleanCap orders.

What critics are saying

  • March 2025 securities litigation over revenue recognition keeps internal-controls failures in focus.
  • Q1 2026 growth still leaned on $14.3 million in COVID CleanCap orders.
  • August 2025 layoffs cut 25% of staff, signaling fragile demand and execution risk.

What makes Maravai LifeSciences unique

  • TriLink and Cygnus sell mission-critical reagents embedded in regulated biomanufacturing workflows.
  • Maravai’s 2026 balance sheet strengthened after June refinancing, extending debt maturity to 2032.
  • The company combines discovery, GMP consumables, and assay kits across genomics and biotherapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
MarketBeat
Aug 25th, 2026
Maravai LifeSciences (NASDAQ:MRVI) sets new 52-week high - still a Buy?

Maravai LifeSciences (NASDAQ:MRVI) sets new 52-week high - still a Buy? August 25, 2026 Key points. * Maravai LifeSciences shares hit a new 52-week high, reaching $8.87 and closing around $8.75, up 3.3% on the session. The stock's market capitalization is approximately $2.26 billion. * Analyst sentiment remains mixed, with two Buy and two Sell ratings producing a consensus "Hold" rating and a $6.25 price target - well below the current share price. * Maravai exceeded quarterly expectations, reporting an adjusted loss of $0.02 per share versus the expected $0.04 loss and revenue of $51.44 million versus estimates of $48.67 million. However, the company remains unprofitable, with negative margins and analysts forecasting a full-year loss. * Five stocks to consider instead of Maravai LifeSciences. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.87 and last traded at $8.7450, with a volume of 1027230 shares traded. The stock had previously closed at $8.43. Analyst upgrades and downgrades. Several equities analysts have weighed in on MRVI shares. Weiss Ratings upgraded Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 29th. UBS Group reissued a "reduce" rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Wall Street Zen raised Maravai LifeSciences from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, Wells Fargo & Company increased their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an "overweight" rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.25. Maravai LifeSciences trading up 3.3%. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -16.76 and a beta of 0.63. The company has a 50-day moving average price of $6.35 and a 200-day moving average price of $4.62. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The business had revenue of $51.44 million during the quarter, compared to analysts' expectations of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. Research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year. Insider buying and selling at Maravai LifeSciences. In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company's stock. Institutional trading of Maravai LifeSciences. A number of hedge funds have recently bought and sold shares of MRVI. Jane Street Group LLC increased its holdings in shares of Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock worth $841,000 after purchasing an additional 356,067 shares during the period. Creative Planning grew its position in Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company's stock worth $280,000 after buying an additional 38,450 shares in the last quarter. Rhumbline Advisers grew its position in Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company's stock worth $471,000 after buying an additional 32,940 shares in the last quarter. Prudential Financial Inc. bought a new position in Maravai LifeSciences during the second quarter valued at about $36,000. Finally, Invesco Ltd. increased its stake in Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company's stock valued at $680,000 after acquiring an additional 40,495 shares during the period. 50.25% of the stock is owned by institutional investors. Maravai LifeSciences company profile. Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Maravai LifeSciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list. While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Business Wire
Jun 23rd, 2026
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
424B4

The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.

MarketScreener
Jun 3rd, 2026
Maravai LifeSciences cuts debt to $150M and extends maturity to 2032

Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.